Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 8/20 | 0.48 |
| ▸ | BRAF | P15056 | 6/20 | 0.45 |
| ▸ | RAF1 | P04049 | 4/20 | 0.45 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.44 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.44 |
| ▸ | CCR2 | P41597 | 1/20 | 0.43 |
| ▸ | MLYCD | O95822 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4263362 | 0.83 | TRPV4 (0.46) | TACR1CCR2 | |
| SCHEMBL30796136 | 0.72 | TACR1 (0.45) | TACR1BRAFRAF1 | |
| SCHEMBL2129300 | 0.72 | TACR1 (0.45) | TACR1BRAFRAF1 | |
| SCHEMBL30794770 | 0.71 | NAPEPLD (0.50) | TACR1BRAFRAF1 | |
| SCHEMBL2129332 | 0.71 | NAPEPLD (0.50) | TACR1BRAFRAF1 | |
| SCHEMBL30794896 | 0.69 | NAPEPLD (0.50) | TACR1BRAFRAF1 | |
| SCHEMBL2130620 | 0.69 | NAPEPLD (0.50) | TACR1BRAFRAF1 | |
| SCHEMBL2129798 | 0.69 | KCNQ3 (0.50) | TACR1BRAFRAF1 | |
| SCHEMBL2130613 | 0.69 | BRAF (0.48) | TACR1BRAFRAF1 | |
| SCHEMBL2130908 | 0.69 | BRAF (0.48) | TACR1BRAFRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1473295-B1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES | KYORIN SEIYAKU KK (JP) | 2009-04-01 | — | — | EP | disclosed |
| US-6995153-B2 | Fused bicyclic pyrimidine derivatives | KYORIN PHARMACEUTICAL. CO., LTD. (JP) | 2006-02-07 | — | — | US | disclosed |
| US-20050085469-A1 | Fused bicyclic pyrimidine derivatives | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2005-04-21 | — | — | US | disclosed |
| EP-1473295-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES | Kyorin Pharmaceutical Co., Ltd. (JP) | 2004-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085469-A1 | Fused bicyclic pyrimidine derivatives | BDKRB1, BDKRB2, TACR1 | TACR1 3/4885BRAF 968/4885RAF1 561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.